Besides opnMe, Koester established scientific crowdsourcing as a new open innovation tool to attract externally generated new therapeutic concepts for Boehringer Ingelheim’s pre-clinical pipeline.
GlobalData on MSN5mon
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drugBoehringer Ingelheim Innovation Unit head Paola Casarosa said: “Zongertinib’s efficacy and tolerability profile has the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback